Recon: FDA to replace some fired workers with contractors; Pfizer abandons development of GLP-1 weight-loss drug
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- The trade war hits pause, but the biotech doom loop carries on (STAT)
- ‘Most-favored nation’ drug pricing has three significant problems (STAT)
- Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity (STAT)
- Inside U.S. health agencies, workers confront chaos and questions as operations come unglued (STAT)
- Novartis plans to invest $23 billion in US sites as Trump renews drug tariff threats (Reuters)
- FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’ (STAT)
- FDA to replace laid-off employees with contractors, sources say (CBS News)
- Pharma tariffs to arrive 'in the next month or two,' commerce secretary says (Endpoints)
- Trump health policy uncertainty sends biotech sector into deeper slump (Reuters)
- European Commission plans emergency measures to combat bird flu in Poland (Reuters)
- WHO members close to accord on tackling future pandemics, sources say (Reuters)
- Canada launches antitrust probe into Cigna's Express Scripts unit (Reuters)
- Medtech Strategy Must Be Priority, German Diagnostics Firms Tell Government (MedTech Insight)
- EU Regulators Push For Better Support For Sponsors On Using Animal Study Alternatives (Pink Sheet)
- Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug (STAT)
- US FDA approves syringe version of Argenx's immune disorder drug (Reuters)
- Novo Nordisk warns consumers about counterfeit versions of Ozempic in US (Reuters)
- Verve gene-editing therapy lowers cholesterol without serious side effects in early study (STAT)
- Biotech investors: Stop expecting CRISPR science to make big leaps (STAT)
- Ironwood to look for alternative paths after FDA asks for another Phase 3 (Endpoints)
- Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer (Endpoints)
- Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty (Endpoints)
- Third Harmonic Bio to shutter; Future Pak once again targets Theratechnologies (Endpoints)
- Tariff turmoil: Hospitals, device makers welcome pause, but fear long-term pain (MedTech Dive)
- Dialysis firm DaVita hit by ransomware attack, says patient care continues (Reuters)
- Birmingham City University Develops New Defense Mechanism Against Cyberattacks On AI Systems (MedTech Insight)
- Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations (MedTech Insight)
- Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market (MedTech Insight)
- Trump to end federal funding of certain non-medical services in Medicaid (STAT)
- Food manufacturers look to stay agile amid tariff uncertainty (Food Dive)
- Why CDC cuts are being called ‘the greatest gift to tobacco industry in the last half-century’ (STAT)
- Closure of CDC hepatitis lab imperils U.S. outbreak response, prevention (STAT)
- Tennessee officials find Express Scripts violated law governing commercial pharmacy claims (STAT)
- Tech modernization at community health centers in limbo after federal workforce cuts (STAT)
- Sandoz files US antitrust lawsuit against Amgen over arthritis drug (Reuters)
- Measles cases in Texas rise to 541, state health department says (Reuters)
- Déjà Vu: OPDP Again Targets Provider Branded Website of Accelerated Approval Drug in Second Untitled Letter of 2025 (FDA Law Blog)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
